Evidence map›Paper›PMID 39791681›Full record

ReviewHealthcare (Basel, Switzerland)2025

The Beneficial Effects of Lactobacillus Strains on Gut Microbiome in Alzheimer's Disease: A Systematic Review.

Michael Quansah, Monique Antoinette David, Ralph Martins, Emad El-Omar, Silvana Mirella Aliberti, Mario Capunzo, Slade O Jensen, Mourad Tayebi

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Michael QuansahNeuroimmunology Laboratory, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Monique Antoinette DavidNeuroimmunology Laboratory, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Ralph MartinsMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Macquarie Park, NSW 2109, Australia.
Emad El-OmarMicrobiome Research Centre, School of Clinical Medicine, UNSW Medicine & Health, St George & Sutherland Clinical Campuses, UNSW, Kogarah, NSW 2217, Australia.ORCID 0000-0002-0011-3924
Silvana Mirella AlibertiHygiene and Preventive Medicine Section, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy.ORCID 0000-0003-3462-6151
Mario CapunzoHygiene and Preventive Medicine Section, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy.
Slade O JensenSchool of Medicine, Microbiology and Infectious Diseases, Ingham Institute for Applied Medical Research, Western Sydney University, Liverpool, NSW 1871, Australia.
Mourad TayebiNeuroimmunology Laboratory, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.ORCID 0000-0001-8664-6918

Funding

Western Sydney University 01
6 · The paper itself

Abstract

BACKGROUND/

objectivesGrowing evidence suggests that the gut-brain axis influences brain function, particularly the role of intestinal microbiota in modulating cognitive processes. Probiotics may alter brain function and behavior by modulating gut microbiota, with implications for neurodegenerative diseases like Alzheimer's disease (AD). The purpose of this review is to systematically review the current literature exploring the effects of probiotic supplementation on gut microbiota and cognitive function in AD and mild cognitive impairment (MCI).

methodsA comprehensive literature search was conducted across PubMed/Medline, Embase, and Scopus to identify relevant randomized controlled trials (RCTs) from inception to 20 August 2024. The search focused on comparing outcomes between intervention and control/placebo groups. Data searches, article selection, data extraction, and risk of bias assessment were performed in accordance with Cochrane guidelines. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration no: CRD42023446796.

resultsData from four RCTs involving 293 Individuals (AD and MCI patients) receiving mainly

conclusionsProbiotics show promise as an adjunctive intervention for cognitive decline, but larger, long-term trials are needed to confirm their efficacy and clinical applicability in neurodegenerative diseases like AD.

Indexed as

Alzheimer’s diseasegut microbiotamild cognitive impairmentprobiotics

Identifiers

PMID39791681
PMCPMC11720007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.